Mazhar Müslüm TUNA, Bercem Aycicek DOGAN, Mehtap Navdar BAŞARAN, Ayşe ARDUÇ, DİLEK BERKER, Serdar GÜLER

Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma

It has been suggested that hyperprolactinemia may be associated with obesity and dyslipidemia. However it is not fully understood that dyslipidemia is occurs independently or due to obesity. The study was aimed to investigate lipid abnormalities and androgen hormone levels before and after cabergolin (CAB) treatment in non- obese premenauposal patients with prolactinoma. This study was a single-centre, prospective, case-control study, consisted of 53 patients with symptomatic prolactinoma (group 1) and 57 healty women (group 3). All subjects underwent a physical examination, anthropometric measurement and a 12 hour fasting blood sample for fasting blood glucose and lipid levels. 49 patients with prolactinoma were reevaluated for metabolic parameters after one year of cabergolin treatment (group 2). The median age was 34 in group 1, and 33 in group 3 (p=0.522). The initially higher body mass index (BMI) in patients with prolactinoma became similar after one year of treatment those with control group (p=0.475). While LDL-C was significanly higher in group 1 than in controls, HDL was significanly lower in group 1. Also post- treatment values of LDL-C (p=0.440) and HDL-C (p=0.612) were not different from the control group. No correlation was found between baseline prolactin levels and FSH, LH, LDL-C, HDL-C (p=0.129, p=0.658, p=0.817, p=0.760 respectively). In conclusion, beneficial metabolic changes were seen in patients with prolactinoma after treatment with cabergoline. Thus considering the metabolic profile and an appropriate treatment goal is important in the clinical management of patients with prolactinoma.

PDF

___

1. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8(1):3-6.

2. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology. 2010;72(3):377-82.

3. Kars M, Dekkers OM, Pereira AM, Romijn JA. Update in prolactinomas. Neth J Med. 2010;68(3):104-12.

4. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17(3):110-6.

5. Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147(1):77-84.

6. Ling C, Svensson L, Odén B, Weijdegård B, Edén B, Edén S, Billig H. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003;88(4):1804-8.

7. Hesmati HM, Turpin G, de Gennes JL. Chronic hyperprolactinaemia and plasma lipids in women. Klin Wochenschr. 1987;65(11):516-9.

8. Jiang XB, Li CL, He DS, Mao ZG, Liu DH, Fan X, Hu B, Zhu YH, Wang HJ. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary. 2014;17(3):232-9.

9. Berinder K, Stackenäs I, Akre O, Hirschberg AL, Hulting AL. Hyperprolactinemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol (Oxf). 2005;63(4):450-5.

10. Delgrange E, Donckier J, Maiter D. Hyperprolactinaemia as a reversible cause of weight gain in male patients? Clin Endocrinol (Oxf). 1999;50(2):271.

11. Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary. 2009;12(2):96-104.

12. Dos SSC, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity. 2011;19(4):800-5.

13. Kopelman PG. Physiopathology of prolactin secretion in obesity. Int J Obes Relat Metab Disord. 2000;24(2):104-8.

14. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006;64(4):366-70.

15. Naliato EC(1), Violante AH, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Souza RG, Costa PL, Colao A. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf). 2007;67(6):845- 52.

16. Nilsson L, Binart N, Bohlooly-Y M, Bramnert M, Egecioglu E, Kindblom J, Kelly PA, Kopchick JJ, Ormandy CJ, Ling C, Billig H. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun. 2005;331(4):1120-6.

17. Tchernof A, Poehlman ET, Després JP. Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab. 2000;26(1):12-20.

18. Berinder K, Nyström T, Höybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14(3):199-207.

19. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G, Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic premenopausal women. Eur J Endocrinol. 2003;149(3):187-93.

20. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012;18(Suppl 1):1-78.

21. Fahy U, Hopton MI, Hartog M, Bolton CH, Hull MG. The lipoprotein profile of women with hyperprolactinemic amenorrhoea. Hum Reprod. 1999;14(2):285-7

22. Kok P, Roelfsema F, Frölich M, van Pelt J, Stokkel MP, Meinders AE, Pijl H. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab. 2006;291(5):1038-43.

23. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23(8):1154-61.

24. Scranton R, Cincotta A. Bromocriptine-unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010;11(2):269-79.